Terms: = Endocrine gland cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
31 results:
1. Molecular analysis of xpo1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
[TBL] [Abstract] [Full Text] [Related]
2. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract] [Full Text] [Related]
3. Identification of miR-30c-5p as a tumor suppressor by targeting the m
Wu Q; Li G; Gong L; Cai J; Chen L; Xu X; Liu X; Zhao J; Zeng Y; Gao R; Yu L; Wang Z
Cancer Med; 2023 Feb; 12(4):5055-5070. PubMed ID: 36259156
[TBL] [Abstract] [Full Text] [Related]
4. Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.
Alzahrani A; Natarajan U; Rathinavelu A
Cancer Genet; 2022 Aug; 266-267():57-68. PubMed ID: 35785714
[TBL] [Abstract] [Full Text] [Related]
5. The abnormal expression of chromosomal region maintenance 1 (crm1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells.
Zhang J; Xu X; Chen Y; Guan X; Zhu H; Qi Y
Bioengineered; 2022 Jan; 13(1):624-633. PubMed ID: 34898375
[TBL] [Abstract] [Full Text] [Related]
6. Rational Combination of crm1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian cancer Cell Lines and Mouse Models.
Handley KF; Rodriguez-Aguayo C; Ma S; Stur E; Joseph R; Bayraktar E; Dasari SK; Nguyen N; Powell RT; Sobieski M; Ivan C; Kim M; Umamaheswaran S; Glassman D; Wen Y; Amero P; Stephan C; Coleman RL; Landesman Y; Westin SN; Ram PT; Sood AK
Mol Cancer Ther; 2021 Dec; 20(12):2352-2361. PubMed ID: 34583979
[TBL] [Abstract] [Full Text] [Related]
7. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to xpo1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract] [Full Text] [Related]
8. Targeting xpo1 and PAK4 in 8505C Anaplastic Thyroid cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract] [Full Text] [Related]
9. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of crm1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract] [Full Text] [Related]
11. FoxO-1 contributes to the efficacy of the combination of the xpo1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract] [Full Text] [Related]
12. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract] [Full Text] [Related]
13. Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of crm1-mediated nuclear export and mTOR-STAT3 pathway.
Shao WY; Yang YL; Yan H; Huang Q; Liu KJ; Zhang S
Cancer Biol Ther; 2017 Jan; 18(1):26-35. PubMed ID: 27981892
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of the Nuclear Export Receptor xpo1 as a Therapeutic Target for Platinum-Resistant Ovarian cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
15. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract] [Full Text] [Related]
16. Identification of Novel Oncogenic Mutations in Thyroid cancer.
Pitt SC; Hernandez RA; Nehs MA; Gawande AA; Moore FD; Ruan DT; Cho NL
J Am Coll Surg; 2016 Jun; 222(6):1036-1043.e2. PubMed ID: 27010584
[TBL] [Abstract] [Full Text] [Related]
17. Novel reversible selective inhibitor of crm1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract] [Full Text] [Related]
18. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic cancer.
Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
[TBL] [Abstract] [Full Text] [Related]
19. xpo1/crm1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
[TBL] [Abstract] [Full Text] [Related]
20. Nuclear FAM21 participates in NF-κB-dependent gene regulation in pancreatic cancer cells.
Deng ZH; Gomez TS; Osborne DG; Phillips-Krawczak CA; Zhang JS; Billadeau DD
J Cell Sci; 2015 Jan; 128(2):373-84. PubMed ID: 25431135
[TBL] [Abstract] [Full Text] [Related]
[Next]
